ADVA launches TeraFlex™ CoreChannel™ for industry’s longest 800G reach
8.6.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 3000 TeraFlex™ CoreChannel™, giving internet content providers (ICPs) and communication service providers (CSPs) the power to transmit 800Gbit/s over greater distances than ever before. Using 140GBd sub-carrier technology, the new CoreChannel™ sled offers the market’s longest reach for a single-channel 800Gbit/s solution, enabling ultra-high-capacity transport over existing and new network infrastructure of more than 1,600km. This provides an improvement in reach of over 50% compared with 95GBd technologies. As well as the longest reach, the sled offers the highest client port flexibility. TeraFlex™ CoreChannel™ can support 400GbE, 100GbE and 10GbE or a mixture of client speeds. The solution is now being trialed by major carriers and R&E network operators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005217/en/
ADVA’s CoreChannel™ transmits 800G data channels 50% farther than any competing solution (Photo: Business Wire)
“Network operators across the planet have been harnessing our FSP 3000 TeraFlex™ to unlock the full potential of their fiber assets. Our compact, plug-and-play terminal offers a simple and cost-efficient way to maximize the capacity of optical infrastructure. Today we’re making it even more powerful with the introduction of our CoreChannel™ sled. Customers can now transport data at 400Gbit/s and 800Gbit/s over longer distances than ever before with a solution that delivers the lowest possible cost per bit per kilometer,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 TeraFlex™ CoreChannel™ technology offers an enormous boost to operators transmitting services across countries and continents. What’s more, long-haul transport with TeraFlex™ CoreChannel™ is even more efficient and reliable thanks to its superior link signal-to-noise (SNR) requirements and higher network performance.”
The launch of ADVA’s CoreChannel™ sled positions the FSP 3000 TeraFlex™ as the industry’s most efficient high-capacity platform for all applications from metro to core to ultra-long-haul submarine links. Compatible with deployed infrastructure, the new solution can transmit 800Gbit/s over more than 1,600km. What’s more, TeraFlex™ CoreChannel™ delivers industry-leading SNR requirements making it resilient to transmission impairments. Along with the bandwidth flexibility and fractional QAM capabilities of the TeraFlex™ terminal, this ensures 800Gbit/s transport with highest efficiency, highest performance and lowest cost. Featuring multi-rate client support, the CoreChannel™ sled can transport any mix of 400GbE, 100GbE and 10GbE services, providing customers with flexibility and protecting their investment as they migrate to higher speeds.
“The launch of our FSP 3000 TeraFlex™ CoreChannel™ changes the game for terrestrial long-haul and regional transport. It gives ICPs and CSPs the ability to inject new capacity into their deployed networks. Now they can drive line speeds of up to 800Gbit/s over distances 50% longer than can be achieved with 95GBd solutions. That advantage will be key to tackling ever-increasing data growth without adding significant cost and complexity,” commented Cornelius Fürst, director, product line management, ADVA. “With its unrivaled reach, multi-rate client flexibility and rich performance settings, TeraFlex™ CoreChannel™ redefines the economics of backbone networks. It will play a key role in accelerating the delivery of high-bandwidth, feature-rich services over ultra-long-haul global infrastructure. And because it can be flexibly configured for lower data rates, it supports a smooth transition to high-speed connectivity.”
Watch this video for more information on the FSP 3000 TeraFlex™ CoreChannel™: https://adva.li/fsp-3000-teraflex-corechannel-product-video.
Further details are also available in this Tech Cam video: https://adva.li/fsp-3000-teraflex-corechannel-tech-cam.
Supporting slides can be viewed here: https://adva.li/fsp-3000-teraflex-corechannel-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005217/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
